Analgesic Nephropathy and Renal Replacement Therapy in Australia

Abstract

Background and objectives: This study examined age-specific incidence and prevalence of renal replacement therapy attributed to analgesic nephropathy from 1971 through 2005 and adjusted comorbidity prevalence and survival of patients who had analgesic nephropathy and were on renal replacement therapy (compared with control subjects without diabetes).Design, setting, participants, & measurements: This retrospective cohort study, using data from the Australia and New Zealand Dialysis and Transplant registry, included all patients who were aged 35 to 84 yr and started long-term renal replacement therapy in Australia from 1971 through 2006.Results: Of 31,654 incident renal replacement therapy patients, 10.2% had analgesic nephropathy. Incidence and prevalence of renal replacement therapy attributed to analgesic nephropathy decreased earlier and faster among younger (age <55 yr) patients. Prevalence of analgesic nephropathy among 75-to 84-yr-old renal replacement therapy patients is still increasing. Compared with control subjects without diabetes, comorbidities (coronary artery, cerebrovascular, peripheral vascular, and chronic lung diseases) were more prevalent among patients with analgesic nephropathy at renal replacement therapy start. All-cause, cardiovascular, infection, and cancer mortality were higher among patients who had analgesic nephropathy and were on renal replacement therapy. For both comorbidities and mortality, the associations were stronger in younger patients.Conclusions: Trends in renal replacement therapy attributed to analgesic nephropathy differed by age. Patients with analgesic nephropathy have more comorbidities and poorer survival on renal replacement therapy, especially among younger patients.

Increases in renal replacement therapy in Australia and New Zealand: Understanding trends in diabetic nephropathy

“…Numbers of analgesic nephropathy patients are decreasing over time, because the offending analgesics were withdrawn in Australia in the 1960s and 1970s 33 . The numbers of incident patients with polycystic kidney disease provide insight into changes in propensity to treat people with end‐stage kidney disease with RRT.…”

Common Analgesic Agents and Their Roles in Analgesic Nephropathy: A Commentary on the Evidence

“…The National Health and Nutritional Examination Survey (NHANES), a large cross-sectional analysis of more than 8,000 random community residents, found no statistically significant difference in the chance of poor renal function between abusers of paracetamol and non-users 229)…”

“…Although a well-recognized condition to most physicians, its etiopathogenesis remains controversial and the particular agents known to induce AN and the cumulative doses required have not been established. Formerly one of the commoner causes of end-stage renal failure (ESRF), there has been a marked decline in the prevalence and incidence of AN in recent decades 12). At its peak in the 1980s, AN accounted for 15% to 20% of cases of ESRF, but has fallen to approximately 1% in Western countries today 34567)…”

Rationales Tumorscreening beim Dialysepatienten

“…Registerdaten zeigen die erhebliche Häufung von Urothelkarzinomen bei diesen Patienten im Vergleich mit aufgrund anderer Grundkrankheiten dialysepflichtigen Patienten. Das absolute Fünfjahresrisiko der Entwicklung eines Urothelkarzinoms ist bei Patienten mit Analgetikanephropathie mit etwa 2 % zu veranschlagen [10]. Damit liegt die Erkrankung bei dieserPatientengruppe anderSpitze derMalignomentitäten und rechtfertigt gezielte Screeningmaßnahmen.…”